Financial Results Summary

Consolidated Financial Results (₹ millions)

Quarter Ended September 30, 2026:

  • Revenue from operations: ₹20,320.97 (22.5% YoY growth)
  • Total income: ₹20,449.45
  • Profit before exceptional items and tax: ₹3,742.21
  • Exceptional items: ₹0 (₹150.89 million in previous quarter)
  • Profit before tax: ₹3,742.21
  • Tax expense: ₹900.09
  • Profit for the period: ₹2,842.12
  • Basic EPS: ₹0.61 (13.3% YoY growth)

Half Year Ended September 30, 2026:

  • Revenue from operations: ₹39,955.80 (25.0% YoY growth)
  • Profit before tax: ₹6,616.99
  • Profit for the period: ₹5,010.23
  • Basic EPS: ₹1.07

Standalone Financial Results (₹ millions)

Quarter Ended September 30, 2026:

  • Revenue from operations: ₹5,751.54
  • Profit before tax: ₹1,299.90
  • Profit for the period: ₹979.44
  • Basic EPS: ₹0.21

Dividend Declaration

  • Interim dividend of ₹0.15 per equity share (face value ₹10 each) for FY 2026-27
  • Record date: October 30, 2026
  • Payment date: On or before November 21, 2026
  • Estimated cash outflow: Approximately ₹702.20 million
  • Previous final dividend of ₹0.10 per share was paid during the current quarter

Business Updates and Acquisitions

CareSeed Acquisition (Completed)

  • Acquired 100% equity interest in CareSeed LLC on June 11, 2026
  • Total contractual consideration: USD 30.0 million (₹2,873.38 million)
  • Contingent consideration: Up to USD 12.5 million (₹1,197.24 million) based on performance targets over 3 years
  • Provisional purchase consideration: USD 21.2 million (₹2,032.51 million)
  • Goodwill recognized: USD 15.7 million (₹1,507.58 million)
  • CareSeed is a US-based healthcare technology company providing quality measurement reporting and risk adjustment solutions

Chirok Health LLC Acquisition (Subsequent Event)

  • Definitive agreement signed on October 21, 2026 through Sagility (US) Holdings Inc.
  • Total consideration: USD 32.35 million (₹3,102.44 million)
  • Contingent consideration: Up to USD 12.35 million (₹1,184.39 million) based on performance targets
  • Chirok Health specializes in Clinical Documentation Integrity, medical coding, Revenue Cycle Management, and audit services
  • Transaction not yet consummated as closing conditions not met as of October 22, 2026

Exceptional Items

  • ₹150.89 million recognized in Q1 FY27 (quarter ended June 30, 2026)
  • Related to past service cost from re-measurement of gratuity and leave encashment liabilities
  • Caused by revised minimum wage rates notified by Karnataka and Telangana governments effective May/June 2026
  • Part of compliance with New Labour Codes implemented by Government of India in November 2025

Key Operational Metrics

  • Total employees: 51,486 as of September 30, 2026 (16.5% YoY growth)
  • Voluntary attrition rate: 25.7% (annualized)
  • Presence in 5 countries with 28 delivery centers
  • 105 active client groups (28 added in H1 FY27 including CareSeed acquisition)
  • $40.2 million ACV from 31 existing clients and 1 new logo

Financial Position (Consolidated)

As of September 30, 2026:

  • Total assets: ₹128,582.74 million
  • Total equity: ₹102,281.01 million
  • Cash and cash equivalents: ₹5,323.12 million
  • Borrowings: ₹4,254.58 million

ESOP Trust

  • Sagility ESOP Trust established on July 7, 2026 for administration of employee stock options
  • No grants issued to employees as of September 30, 2026

Management Commentary

Ramesh Gopalan, MD and Group CEO, highlighted strong H1 FY27 performance with broad-based momentum, healthy pipeline, AI solution traction, and successful integration of CareSeed. Srinivas Mattapalli, Group CFO, noted disciplined execution, robust cash generation, and highest adjusted EBITDA margin in six quarters.